# A Study of CRD3874-SI in People With Leukemia

> **NCT07661095** · PHASE1 · RECRUITING · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 24 (estimated)

## Conditions studied

- Acute Myeloid Leukemia
- AML
- Refractory Acute Myeloid Leukemia

## Interventions

- **DRUG:** CRD3874-SI

## Key facts

- **NCT ID:** NCT07661095
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-06-15
- **Primary completion:** 2028-06-15
- **Final completion:** 2028-06-15
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2026-09-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07661095

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07661095, "A Study of CRD3874-SI in People With Leukemia". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07661095. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*